

## Instructions to Authors 2014

*General Policy.* IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide prompt (print and online) publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC - IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

*Ethical Policies and Standards.* IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: <http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org) (mail to: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:  
John G. Delinasios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH,  
IN VIVO and CANCER GENOMICS & PROTEOMICS, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014 Kapandriti,  
Attiki, GREECE.

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2014 are entitled to a complimentary online subscription of IN VIVO 2014. Requests should be addressed to the Editorial Office.

Copyright© 2014 International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Contents continued

Postsurgical Pain Related to Breast Implant: Reduction with Lipofilling Procedure. R. CUOMO, I. ZERINI, G. BOTTERI, L. BARBERI, G. NISI, C. D'ANIELLO ( <i>Siena, Italy</i> ) .....	993
Surgical Treatment to Aid Patients with Colorectal Perforation. H. ONISHI, K. SUMIYOSHI, R. TERASAKA, M. KATANO ( <i>Fukuoka, Japan</i> ) .....	997
EORTC QLQ-BM22 Quality of Life Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with Zoledronic Acid. D.-C. YEH, D.-R. CHEN, T.-Y. CHAO, S.-C. CHEN, H.-C. WANG, K.-M. RAU, Y.-H. FENG, Y.-C. CHANG, K.-D. LEE, F. OU-YANG, W.-H. KUO, K.-J. CHANG, Y.-C. LIN, L.-M. TSENG, M.-F. HOU ( <i>Taichung; Changhua; New Taipei City; Taipei; Kaohsiung; Tainan; Chiayi; Taoyuan, Taiwan, ROC</i> ) .....	1001

Association of <i>SUMO4</i> M55V and -94Ins/Del Gene Variants with Type-2 Diabetes. S. SOZEN, C. HOROZOGLU, E. S. BIRELLER, Z. KARAALI, B. CAKMAKOGLU ( <i>Istanbul, Turkey</i> ) .....	919
Synergistic Effect of Sorafenib with Ionizing Radiation on Human Oral Cancer Cells. F.-T. HSU, B. CHANG, I.-T. CHIANG, T.-H. WU, J.-J. HWANG ( <i>Taipei; Taichung, Taiwan, ROC</i> ).....	925
Lipid Lipoprotein Profile Alterations in Greek Infertile Women with Polycystic Ovaries: Influence of Adipocytokines Levels. I. TSOUMA, E. KOUSKOUNI, S. DEMERIDOU, M. BOUTSIKOU, D. HASSIAKOS, A. CHASIAKOU, S. HASSIAKOU, V. GENNIMATA, S. BAKA ( <i>Athens, Greece</i> ) .....	935
 <i>Clinical Studies</i>	
Progressive Multifocal Leukoencephalopathy – A Case Report and Review of the Literature. E. SMOLLE, A. TROJAN, S. J. SCHUSTER, J. HAYBAECK ( <i>Graz, Austria; Zurich, Switzerland; Philadelphia, PA, USA</i> ) .....	941
Diffuse-type Tenosynovial Giant Cell Tumor with t(1;17)(p13;p13) and Trisomy 5. J. NISHIO, Y. KAMACHI, H. IWASAKI, M. NAITO ( <i>Fukuoka, Japan</i> ).....	949
Urinary Neopterin Concentrations During Combination Therapy with Cetuximab in Previously Treated Patients with Metastatic Colorectal Carcinoma. B. MELICHAR, H. KALÁBOVÁ, L. KUJOVSKÁ KRČMOVÁ, S. VIPIN TRIVEDI, P. KRALÍČKOVÁ, E. MALÍŘOVÁ, M. PECKA, H. ŠTUDENTOVÁ, M. ZEŽULOVÁ, P. HOLEČKOVÁ, D. SOLICHOVÁ ( <i>Olomouc; Hradec Králové, Czech Republic</i> )....	953
Successful Treatment of Panton-Valentine Leukocidin-expressing <i>Staphylococcus aureus</i> -associated Pneumonia Co-infected with Influenza Using Extracorporeal Membrane Oxygenation. N. FUJISAKI, A. TAKAHASHI, T. ARIMA, T. MIZUSHIMA, K. IKEDA, H. KAKUCHI, A. NAKAO, J. KOTANI, K. SAKAIDA ( <i>Nishinomiya; Funabashi, Japan</i> ).....	961
Effects of Interleukin-10 Polymorphisms and Smoking on the Risk of Gastric Cancer in Taiwan. W.-H. KUO, C.-Y. HUANG, C.-K. FU, Y.-H. HSIEH, C.-H. LIAO, C.-M. HSU, Y.-K. HUANG, C.-W. TSAI, W.-S. CHANG, D.-T. BAU ( <i>Kaoshiung; Taichung; Taipei, Taiwan, ROC</i> ) .....	967
Anger in Health, Benign Breast Disease and Breast Cancer: A Prospective Case–Control Study. A. BRUNO, G. PANDOLFO, G. SCIMECA, V. LEONARDI, C. CEDRO, S. RACCHIUSA, R. A. ZOCCALI, M. R. A. MUSCATELLO ( <i>Messina, Italy</i> ) .....	973
Complementary Medicine Down-regulates Side-effects of Hormone Therapy in Prostate Cancer Patients. J. BEUTH, R. VAN LEENDERT, K. PEMPELFORT, B. SCHNEIDER, C. GRUND, U. ENGELMANN ( <i>Cologne; Düsseldorf; Hannover, Germany</i> ) .....	979
The Evaluation of Angiotensin-converting Enzyme ( <i>ACE</i> ) Gene I/D and <i>IL-4</i> Gene Intron 3 VNTR Polymorphisms in Coronary Artery Disease. N. BASOL, A. CELIK, N. KARAKUS, S. D. OZSOY, S. YIGIT ( <i>Tokat, Turkey</i> ).....	983
Leptin Levels in Women with Polycystic Ovaries Undergoing Ovarian Stimulation: Relation to Lipoprotein Profiles. I. TSOUMA, E. KOUSKOUNI, V. GENNIMATA, S. DEMERIDOU, M. BOUTSIKOU, V. GRIGORIOU, A. CHASIAKOU, S. HASSIAKOU, S. BAKA ( <i>Athens, Greece</i> ).....	989

The Expression of <i>MTNR3</i> and Nuclear Receptors in Murine Leucocytes. V. CERNYSIOV, R. BOZAITA, M. MAURICAS, I. GIRKONTAITE ( <i>Vilnius, Lithuania</i> ) .....	827
Influence of Circadian Time and Lighting Conditions on Expression of Melatonin Receptors 1 and 2 in Murine Lymphocytes. V. CERNYSIOV, R. BOZAITA, M. MAURICAS, I. GIRKONTAITE ( <i>Vilnius, Lithuania</i> ) .....	831
Evaluation of the Immunological Cellular Response of <i>Cebus apella</i> Exposed to the Carcinogen <i>N</i> -Methyl- <i>N</i> -nitrosourea and Treated with CANOVA <sup>®</sup> . D. C. AZEVEDO FEIO, J. A. PEREIRA CARNEIRO MUNIZ, R. CARVALHO MONTENEGRO, R. RODRIGUEZ BURBANO, L. CARDOSO DE BRITO JUNIOR, P. D. LIMA DE LIMA ( <i>Belém, PA; Ananindeua, PA, Brazil</i> ) .....	837
The Effect of Common Antineoplastic Agents on Induction of Apoptosis in Canine Lymphoma and Leukemia Cell Lines. A. PAWLAK, A. RPAK, I. ZBYRYT, B. OBMIŃSKA-MRUKOWICZ ( <i>Wroclaw, Poland</i> ) .....	843
Alterations in miRNA Expression Patterns in Whole Blood of OSCC Patients. J. RIES, E. VAIRAKTARIS, R. KINTOPP, C. BARAN, F. W. NEUKAM, E. NKENKE ( <i>Erlangen; Halle, Germany; Athens, Greece</i> ) .....	851
Use of Surgery and Carboplatin in Feline Malignant Mammary Gland Neoplasms with Advanced Clinical Staging. C. BONOLO DE CAMPOS, F. CAMARGO NUNES, G. EUNICE LAVALLE, G. DANTAS CASSALI ( <i>Jaboticabal; Belo Horizonte, Brazil</i> ) .....	863
Additional Compensatory Mechanisms Altering Antisense Oligonucleotide Suppression of BCL2: Effects upon AKT1 and STAT3. M. RUBENSTEIN, C. M. P. HOLLOWELL, P. GUINAN ( <i>Chicago, IL, USA</i> ) .....	867
VEGF and 17- $\beta$ -estradiol Levels After Tamoxifen Administration in Canine Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas. A. SOBCZYŃSKA-RAK, A. BRODZKI ( <i>Lublin, Poland</i> ) .....	871
Corticosterone Metabolites Originating as a Consequence of Solvated Electron ( $e_{aq}^-$ ) Emission. E. BRENN, G. MITULOVIĆ, R.-M. QUINT, N. GETOFF ( <i>Vienna, Austria</i> ) .....	879
The Relationship Between <i>ACE</i> Polymorphism and Panic Disorder. S. GULEC-YILMAZ, H. GULEC, A. BURAK DALAN, B. CETİN, O. TİMİRCİ-KAHRAMAN, D. BİLGE OGUT, H. ATASOY, G. ARIKAN DİRİMEN, G. INAL GULTEKİN, T. ISBİR ( <i>Istanbul, Turkey</i> ) .....	885
Phenethyl Isothiocyanate Inhibits <i>In Vivo</i> Growth of Subcutaneous Xenograft Tumors of Human Malignant Melanoma A375.S2 Cells. W.-Y. NI, H.-F. LU, S.-C. HSU, Y.-P. HSIAO, K.-C. LIU, J.-Y. LIU, B.-C. JI, S.-C. HSUEH, F.-M. HUNG, H.-S. SHANG, J.-G. CHUNG ( <i>Caotun; Taipei; Taichung; Changhua, Taiwan, ROC</i> ) .....	891
Effects of TiO <sub>2</sub> Nano Glass Ionomer Cements Against Normal and Cancer Oral Cells. R. GARCIA-CONTRERAS, R. J. SCOUGALL-VILCHIS, R. CONTRERAS-BULNES, Y. KANDA4, H. NAKAJIMA, H. SAKAGAMI ( <i>Toluca, Mexico; Saitama, Japan</i> ) .....	895
Mn Complex-mediated Enhancement of Antitumor Response Through Modulating Myeloid-derived Suppressor Cells in Drug-resistant Tumor. S. DAS, K. BANERJEE, S. ROY, S. MAJUMDER, M. CHATTERJEE, S. MAJUMDAR, S. K. CHOUDHURI ( <i>Kolkata, India</i> ) .....	909

Perfusion of a Cerebral Protective Solution Enhances Neuroprotection in a Rabbit Model of Occlusion-Reperfusion: Prolonged Cerebral Dormancy Time. L. YE, A. HUA, B. DAI, T. LU, Z. ZHANG, M. YE, M. WEINTRAUB, Q. Q. LI ( <i>Nanning, PR China; Bethesda, MD, USA</i> ) .....	727
Bone Substitutes Enhance Osteogenic Differentiation of Mesenchymal Stem Cells in Three-dimensional Scaffolds. H. HANKEN, J. ALPERS, M. BÖBEL, M. WÖLTJE, P. HARTJEN, R. E. FRIEDRICH, O. JUNG, C. RENDENBACH, A. GRÖBE, M. HEILAND, A. AL-DAM, W. EICHHORN, R. SMEETS ( <i>Hamburg; Aachen, Germany</i> ) .....	733
The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H. S. DARUSMAN, O. KALLIOKOSKI, D. SAJUTHI, S. J. SCHAPIRO, A. GJEDDE, J. HAU ( <i>Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Montreal, QC, Canada; Bastrop, TX; Baltimore, MD, USA</i> ).....	741
Expression of Livin and the Inhibition of Tumor Progression by Livin Silencing in Laryngohypopharyngeal Cancer. T. M. YOON, S.-A. KIM, D. H. LEE, J. K. LEE, Y.-L. PARK, K.-H. LEE, I.-J. CHUNG, Y.-E. JOO, S. C. LIM ( <i>Gwanju, South Korea</i> ).....	751
Validation of an HPV16-mediated Carcinogenesis Mouse Model. K. DE AZAMBUJA, P. BARMAN, J. TOYAMA, D. ELASHOFF, G. W. LAWSON, L. K. WILLIAMS, K. CHUA, D. LEE, J. J. KEHOE, A. BRODKORB, R. SCHWIEBERT, S. KITCHEN, A. BHIMANI, D. J. WILEY ( <i>Los Angeles, CA; Houston, TX, USA; Fermoy, Ireland</i> ).....	761
Heparanase, a Potential Marker for Premalignant Oral Cavity Cancer. Y. LEISER, D. SHILO, I. A. EL NAAJ, A. RACHMIEL ( <i>Haifa, Israel</i> ) .....	769
Establishment of Nude Mice with Complete Loss of Lymphocytes and NK Cells and Application for <i>In Vivo</i> Bio-imaging. R. KARIYA, K. MATSUDA, K. GOTOH, K. VAETEEWOOTTACHARN, S. HATTORI, S. OKADA ( <i>Kumamoto, Japan</i> ) .....	779
Efficient Utilization of Licorice Root by Alkaline Extraction. H. OHNO, S. MIYOSHI, D. ARAHO, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, T. TSUDA, K. SUNAGA, S. AMANO, E. OHKOSHI, H. SAKAGAMI, K. SATOH, M. YAMAMOTO ( <i>Tokyo; Kanagawa; Saitama, Japan</i> ) .....	785
Influence of Static Magnetic Fields Combined with Human Insulin-like Growth Factor 1 on Human Satellite Cell Cultures. R. BIRK, J. U. SOMMER, D. HAAS, A. FABER, C. ADERHOLD, J. D. SCHULTZ, K. HOERMANN, J. STERN-STRAETER ( <i>Mannheim, Germany</i> ).....	795
Healthy Lung Tissue Response to Mechanical Ventilation in an Experimental Porcine Model. J. FREMUTH, J. KOBR, K. PIZINGEROVA, L. SASEK, P. JEHLICKA, J. ZAMBORYOVA, O. HESS, J. VRZALOVA, J. RACEK, Z. TONAR ( <i>Pilsen, Czech Republic</i> ) .....	803
Evaluation of <i>Hirsutella sinensis</i> Mycelium on Food Safety and Anti-hepatoma Activity in an Animal Model. H.-S. SHANG, J. CHOU, M.-F. WU, Y.-L. SHIH, M.-Y. YEH, H.-Y. CHUNG, H.-F. LU, N.-C. LIAO, J. Y. LIU, S.-C. HSUEH, J.-G. CHUNG ( <i>Taipei; New Taipei City; Houlong; Taichung, Taiwan, ROC</i> ).....	811
Sodium Caseinate Induces Increased Survival in Leukaemic Mouse J774 Model. Y. CÓRDOVA-GALAVIZ, E. LEDESMA-MARTÍNEZ, I. AGUÍÑIGA-SÁNCHEZ, G. SOLDEVILA-MELGAREJO, I. SOTO-CRUZ, B. WEISS-STEIDER, E. SANTIAGO-OSORIO ( <i>Mexico City, Mexico</i> ) .....	819